{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:40:48Z","timestamp":1761946848652,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16505 20K16136"],"award-info":[{"award-number":["19K16505 20K16136"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Oseltamivir has been shown to prolong the atrial conduction time and effective refractory period, and to suppress the onset of burst pacing-induced atrial fibrillation <jats:italic>in vitro<\/jats:italic>. To better predict its potential clinical benefit as an anti-atrial fibrillatory drug, we performed translational studies by assessing <jats:italic>in vivo<\/jats:italic> anti-atrial fibrillatory effect along with <jats:italic>in vivo<\/jats:italic> and <jats:italic>in vitro<\/jats:italic> electropharmacological analyses. Oseltamivir in intravenous doses of 3 (n = 6) and 30\u00a0mg\/kg (n = 7) was administered in conscious state to the persistent atrial fibrillation model dogs to confirm its anti-atrial fibrillatory action. The model was prepared by tachypacing to the atria of chronic atrioventricular block dogs for &amp;gt; 6\u00a0weeks. Next, oseltamivir in doses of 0.3, 3 and 30\u00a0mg\/kg was intravenously administered to the halothane-anesthetized intact dogs to analyze its <jats:italic>in vivo<\/jats:italic> electrophysiological actions (n = 4). Finally, its <jats:italic>in vitro<\/jats:italic> effects of 10\u20131,000\u00a0\u03bcM on I<jats:sub>K,ACh<\/jats:sub>, I<jats:sub>Kur<\/jats:sub>, I<jats:sub>Kr<\/jats:sub>, I<jats:sub>Na<\/jats:sub> and I<jats:sub>CaL<\/jats:sub> were analyzed by using cell lines stably expressing Kir3.1\/3.4, K<jats:sub>V<\/jats:sub>1.5, hERG, Na<jats:sub>V<\/jats:sub>1.5 or Ca<jats:sub>V<\/jats:sub>1.2, respectively (n = 3 for I<jats:sub>K,ACh<\/jats:sub> and I<jats:sub>Kr<\/jats:sub> or n = 6 for I<jats:sub>Kr<\/jats:sub>, I<jats:sub>Na<\/jats:sub> and I<jats:sub>CaL<\/jats:sub>). Oseltamivir in doses of 3 and 30\u00a0mg\/kg terminated the atrial fibrillation in 1 out of 6 and in 6 out of 7 atrial fibrillation model dogs, respectively without inducing any lethal ventricular arrhythmia. Its 3 and 30\u00a0mg\/kg delayed inter-atrial conduction in a frequency-dependent manner, whereas they prolonged atrial effective refractory period in a reverse frequency-dependent manner in the intact dogs. The current assay indicated that IC<jats:sub>50<\/jats:sub> values for I<jats:sub>K,ACh<\/jats:sub> and I<jats:sub>Kr<\/jats:sub> were 160 and 231\u00a0\u03bcM, respectively, but 1,000\u00a0\u00b5M inhibited I<jats:sub>Na<\/jats:sub>, I<jats:sub>CaL<\/jats:sub> and I<jats:sub>Kur<\/jats:sub> by 22, 19 and 13%, respectively. The extent of I<jats:sub>Na<\/jats:sub> blockade was enhanced at faster beating rate and more depolarized resting membrane potential. Oseltamivir effectively terminated the persistent atrial fibrillation, which may be largely due to the prolongation of the atrial effective refractory period and inter-atrial conduction time induced by I<jats:sub>K,ACh<\/jats:sub> and I<jats:sub>Kr<\/jats:sub> inhibitions along with I<jats:sub>Na<\/jats:sub> suppression. Thus, oseltamivir can exert a powerful anti-atrial fibrillatory action through its ideal multi-channel blocking property; and oseltamivir would become a promising seed compound for developing efficacious and safe anti-atrial fibrillatory drugs.<\/jats:p>","DOI":"10.3389\/fphar.2021.593021","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T08:19:31Z","timestamp":1619684371000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Translational Studies on Anti-Atrial Fibrillatory Action of Oseltamivir by its in vivo and in vitro Electropharmacological Analyses"],"prefix":"10.3389","volume":"12","author":[{"given":"Ryuichi","family":"Kambayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Izumi-Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Tsurudome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Ohshiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Hagiwara-Nagasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Nunoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1161\/CIRCULATIONAHA.115.018016","article-title":"Potassium channel blockade enhances atrial fibrillation-selective antiarrhythmic effects of optimized state-dependent sodium channel blockade","volume":"132","author":"Aguilar","year":"2015","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/ehjcvp\/pvy022","article-title":"A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation","volume":"5","author":"Camm","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1161\/CIRCULATIONAHA.105.575332","article-title":"The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation","volume":"112","author":"Dobrev","year":"2005","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00210-017-1415-y","article-title":"The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model","volume":"390","author":"Frommeyer","year":"2017","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ejphar.2015.06.004","article-title":"Oseltamivir produces hypothermic and neuromuscular effects by inhibition of nicotinic acetylcholine receptor functions: comparison to procaine and bupropion","volume":"762","author":"Fukushima","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1113\/jphysiol.2006.126714","article-title":"Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart","volume":"582","author":"Gaborit","year":"2007","journal-title":"J. Physiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1161\/01.cir.96.11.4027","article-title":"Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model","volume":"96","author":"Gaspo","year":"1997","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"581837","DOI":"10.3389\/fphar.2020.581837","article-title":"Revisiting antiarrhythmic drug therapy for atrial fibrillation: reviewing lessons learned and redefining therapeutic paradigms","volume":"11","author":"Geng","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B9","first-page":"228","article-title":"Agents used in cardiac arrhythmias","volume-title":"The basic & clinical Pharmacology","author":"Harvey","year":"2018"},{"key":"B10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/13543784.2017.1353601","article-title":"Investigational antiarrhythmic agents: promising drugs in early clinical development","volume":"26","author":"Heijman","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1254\/jphs.09061sc","article-title":"Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs","volume":"110","author":"Iwasaki","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/clpt.2014.155","article-title":"Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil","volume":"96","author":"Johannesen","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00380-020-01612-1","article-title":"Analysis of electropharmacological effects of AVE0118 on the atria of chronic atrioventricular block dogs: characterization of anti-atrial fibrillatory action by atrial repolarization-delaying agent","volume":"35","author":"Kambayashi","year":"2020","journal-title":"Heart Vessels"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: reporting in vivo experiments: the ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12012-013-9202-6","article-title":"Cardiohemodynamic and electrophysiological effects of anti-influenza drug oseltamivir in vivo and in vitro","volume":"13","author":"Kitahara","year":"2013","journal-title":"Cardiovasc. Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00003495-200161020-00011","article-title":"Oseltamivir: a review of its use in influenza","volume":"61","author":"McClellan","year":"2001","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/j.1476-5381.2010.00873.x","article-title":"Guidelines for reporting experiments involving animals: the ARRIVE guidelines","volume":"160","author":"McGrath","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jphs.2016.04.018","article-title":"Intravenous anti-influenza drug oseltamivir will not induce torsade de pointes: evidences from proarrhythmia model and action-potential assay","volume":"131","author":"Nakamura","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"B19","unstructured":"JCS\/JHRS 2020 Guideline on pharmacotherapy of cardiac arrhythmias. The japanese circulation society\/japanese heart rhythm society Joint Guidelines\n            OnoK.\n            IwasakiY.\n            ShimizuW.\n            AkaoM.\n            IkedaT.\n            IshiiK.\n          2020"},{"key":"B20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/B978-0-323-44733-1.00031-6","article-title":"Ionic mechanisms of atrial action potentials","volume-title":"\u201cThe cardiac electrophysiology from cell to bedside","author":"Pandit","year":"2018"},{"key":"B21","doi-asserted-by":"publisher","first-page":"104262","DOI":"10.1016\/j.phrs.2019.104262","article-title":"Atria-selective antiarrhythmic drugs in need of alliance partners","volume":"145","author":"Peyronnet","year":"2019","journal-title":"Pharmacol. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2165\/11204960-000000000-00000","article-title":"Pilsicainide","volume":"70","author":"Plosker","year":"2010","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1254\/jjp.81.79","article-title":"Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters","volume":"81","author":"Satoh","year":"1999","journal-title":"Jpn. J. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1006\/taap.1998.8494","article-title":"Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring","volume":"152","author":"Sugiyama","year":"1998","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/bjp.2008.240","article-title":"Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts","volume":"154","author":"Sugiyama","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1248\/bpb.b13-00347","article-title":"Electrophysiological effects of an anti-influenza drug oseltamivir on the Guinea-pig atrium: comparison with those of pilsicainide","volume":"36","author":"Takahara","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/BF01744586","article-title":"Simultaneous assessment of the hemodynamic, cardiomechanical, and electrophysiological effects of terfenadine on the in vivo canine model","volume":"13","author":"Usui","year":"1998","journal-title":"Heart Vessels"},{"key":"B28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","article-title":"An improved method to correct the QT interval of the electrocardiogram for changes in heart rate","volume":"22","author":"Van de Water","year":"1989","journal-title":"J. Pharmacol. Methods"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1161\/01.cir.92.7.1954","article-title":"Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats","volume":"92","author":"Wijffels","year":"1995","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1113\/jphysiol.2006.126714","article-title":"G protein regulation of potassium ion channels","volume":"50","author":"Yamada","year":"1998","journal-title":"Pharmacol. Rev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.593021\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T08:20:14Z","timestamp":1619684414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.593021\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":30,"alternative-id":["10.3389\/fphar.2021.593021"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.593021","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"article-number":"593021"}}